BOTHELL, Wash.--(BUSINESS WIRE)--Plexera Bioscience LLC, a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA), announced today an option agreement with Auguron Biosciences, Inc, giving them rights to exclusive access to use Auguron’s Nucleic Acid Programmable Protein Array (NAPPA) technology on the Plexera Kx™ Array Platform.
